FSSAI opens three cases against Nestlé India over infant-formula claims
India’s food regulator has initiated three adjudication cases involving Nestlé infant-formula products, citing allegedly prohibited promotional claims and biotin-standard violations. The action raises compliance and reputation risks for NAN Excella Pro Stage 1 and Lactogen Pro 1.
What happened
FSSAI has initiated three adjudication cases against Nestle India over prohibited promotional claims and biotin-standard violations involving infant formula
Key facts
- 5 HMOs
- 3 adjudication cases
- nearly 2% share-price decline
- Section 3 of the IMS Act, 1992
- Regulation 4(2) of the 2020 Infant Nutrition Regulations
Why this matters
Potential partners and acquirers should treat infant-nutrition regulatory diligence as a priority in India, where claim substantiation and formulation compliance can materially affect asset value.
What to watch
- FSSAI adjudication notices specifying the alleged claims, biotin measurements, affected batches and proposed penalties.
- Any direction to stop sale, recall, relabel or remove digital promotional materials.
- Nestlé India disclosures on provisions, product withdrawals, sales impact or regulatory correspondence.
- E-commerce and pharmacy-platform changes to infant-formula search placement, promotions or listing requirements.
- Follow-on inspections or notices involving other infant-formula manufacturers.
- Consumer and pediatrician sentiment, including social-media amplification linking the action to product safety rather than advertising compliance.
- Audit all India infant-nutrition claims, pack copy, e-commerce listings, influencer content and healthcare-professional engagement against FSSAI and infant-milk-substitute rules.
- Prepare batch-level biotin testing, supplier documentation and product-release records for NAN Excella Pro Stage 1 and Lactogen Pro 1.
- Ring-fence affected SKUs with revised artwork and contingency inventory plans to prevent broad portfolio disruption.
- Strengthen pharmacist, pediatrician and consumer-service communications around product safety, nutrition compliance and any labeling updates.
- Model retailer and e-commerce delisting risk, particularly where platforms may remove promotional content before formal adjudication concludes.